{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-hodgkin%27s+Lymphoma&page=3", "query": { "condition": "Non-hodgkin's Lymphoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2188, "total_pages": 219, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-hodgkin%27s+Lymphoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-hodgkin%27s+Lymphoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T12:35:49.543Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02057445", "title": "3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkins Lymphoma", "Hodgkins Lymphoma", "Lymphoproliferative Disorder" ], "interventions": [ { "name": "EBV CTL's", "type": "DRUG" }, { "name": "Peripheral Blood Donor", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 1, "start_date": "2014-01", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Valhalla, New York", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057445" }, { "nct_id": "NCT03297424", "title": "A Study of PLX2853 in Advanced Malignancies.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer", "Uveal Melanoma", "Ovarian Clear Cell Carcinoma", "Non-Hodgkin Lymphoma", "Advanced Malignancies", "Solid Tumor", "Diffuse Large B Cell Lymphoma", "Follicular Lymphoma" ], "interventions": [ { "name": "PLX2853", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Opna Bio LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2017-09-12", "completion_date": "2021-06-07", "has_results": false, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Miami, Florida • New York, New York + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03297424" }, { "nct_id": "NCT00070382", "title": "Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "darbepoetin alfa", "type": "DRUG" }, { "name": "epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070382" }, { "nct_id": "NCT00168727", "title": "Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Low-Grade" ], "interventions": [ { "name": "ibritumomab tiuxetan (Zevalin®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2003-06-01", "completion_date": "2005-10-31", "has_results": false, "last_update_posted_date": "2023-08-23", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 8, "location_summary": "Loma Linda, California • Oceanside, California • Fairfield, Connecticut + 5 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Elk Grove Village", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00168727" }, { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT00003805", "title": "Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bone Marrow Suppression", "Fever, Sweats, and Hot Flashes", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "piperacillin sodium", "type": "DRUG" }, { "name": "piperacillin-tazobactam", "type": "DRUG" }, { "name": "tazobactam sodium", "type": "DRUG" }, { "name": "vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "European Organisation for Research and Treatment of Cancer - EORTC", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 859, "start_date": "1997-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-09-24", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Boston, Massachusetts", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003805" }, { "nct_id": "NCT04906096", "title": "Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Central Nervous System Lymphoma", "Non-Hodgkin Lymphoma of Extranodal Site" ], "interventions": [ { "name": "PAXALISIB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lakshmi Nayak, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-06-01", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906096" }, { "nct_id": "NCT03467373", "title": "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Lymphoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab (G)", "type": "DRUG" }, { "name": "Rituximab (R)", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-03-13", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 3, "location_summary": "Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03467373" }, { "nct_id": "NCT05938127", "title": "Impact of Respiratory Training in Lymphoma Survivors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hodgkin Lymphoma", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "Inspiratory muscle strength training", "type": "DEVICE" }, { "name": "Sham Inspiratory muscle strength training", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 1, "start_date": "2024-09-16", "completion_date": "2024-12-09", "has_results": true, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 2, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05938127" }, { "nct_id": "NCT03373305", "title": "Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD30-Positive Neoplastic Cells Present", "Folliculotropic Mycosis Fungoides", "Recurrent Mycosis Fungoides", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Mycosis Fungoides", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-03", "completion_date": "2019-04-26", "has_results": false, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-10-09T12:35:49.543Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03373305" } ] }